JNJ-63898081 (JNJ-081) is a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells, aiming to overcome immunosuppression and promoting antitumor activity. Patients and methods: We conducted a phase 1 dose escalation study of JNJ-081 in patients with metastatic castration-resistance prostate cancer (mCRPC).

JNJ-8081: 一种ADCC、T淋巴细胞刺激剂药物，由Johnson & Johnson (Johnson & Johnson)公司最早进行研发，目前全球最高研发状态为无进展，作用机制: ADCC (抗体依赖的细胞毒作用),T淋巴细胞刺激剂，治疗领域: 肿瘤,泌尿生殖系统疾病。

JNJ-63898081 (JNJ-081) is a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells, aiming to overcome immunosuppression and promoting antitumor activity. We conducted a phase 1 dose escalation study of JNJ-081 in patients with metastatic castration-resistance prostate cancer (mCRPC).

2021年1月29日 · In this analysis of the Phase 1 CHRYSALIS study, investigators assessed the efficacy and safety of amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations, who had progressed on prior platinum-based chemotherapy, and were treated at the recommended Phase 2 dose (RP2D of 1050 mg [1400 mg for a …

JNJ-081 是一种双特异性抗体，一个臂结合癌细胞上的 PSMA，另一个结合 T 细胞上的 CD3，以促进抗肿瘤活性。 方法： 这项 1 期剂量递增研究评估了在新型雄激素靶向治疗（例如，阿比特龙、恩杂鲁胺或阿帕鲁胺）后进展的 mCRPC 参与者 (pts) 中的 JNJ-081。 允许预先化疗。 JNJ-081 最初通过静脉内 (IV) 给药，然后通过皮下 (SC) 途径给药。 剂量递增遵循基于贝叶斯回归模型的连续重新评估方法。 确定推荐的第 2 期剂量 (RP2D) 的主要终点是基于安全性。 还评估了药代 …

Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus PSMA Protein, His,Avitag (Cat. No. PSA-C82Q6) with a linear range of 0.5-16 ng/mL (QC tested). The biotinylated PSMA protein was conjugated to streptavidin magnetic beads.

2025年3月20日 · JNJ-8081: a ADCC, T lymphocytes stimulants Drug, Initially developed by Johnson & Johnson, Now, its global highest R&D status is Pending, Mechanism: ADCC (Antibody-dependent cell-mediated cytotoxicity (ADCC) effects),T lymphocytes stimulants, Therapeutic Areas: Neoplasms,Urogenital Diseases.

2022年2月16日 · JNJ-081 is a bispecific antibody with one arm binding PSMA on cancer cells and the other binding CD3 on T-cells to promote anti-tumor activity. Methods: This Phase 1 Dose Escalation Study evaluated JNJ-081 in mCRPC participants (pts) who progressed after novel androgen targeting therapy (eg, abiraterone, enzalutamide or apalutamide).

Study agent JNJ-081 was administered by intravenous (IV) infusion and then via subcutaneous (SC) route. Bayesian regression modeling was used for continuous reassessment during dose escalation. The primary endpoint of this study evaluate safety to determine the recommended phase II dose (RP2D).

jnj-63898081是由强生创新制药研发的一种双特异性抗体，目前该药物最高研发阶段为临床一期，用于治疗肿瘤。 JNJ-63898081-靶点: PSMA_适应症: 肿瘤-临床_专利_批准